Sunil Healthcare Reports Negative Financial Results for Q4 2023

Sunil Healthcare, a microcap pharmaceutical company, recently announced its financial results for the quarter ending December 2023. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.

According to the financial report, Sunil Healthcare has seen a negative performance in the quarter, with a score of -19 compared to -18 in the previous quarter. This indicates a decline in the company's financial health.

One of the major factors contributing to this decline is the Profit Before Tax (PBT) less Other Income, which has fallen to -185.6% over the average PBT of the previous four quarters. This shows a significant decrease in the company's profitability. Additionally, the company's ability to manage interest payments has also deteriorated, with the Operating Profit to Interest ratio being at its lowest in the last five quarters.

The company's sales have also been affected, with a negative trend in the near term. The Net Sales for the nine-month period have shown a decline of -22.81% year on year, while the Profit After Tax (PAT) has also decreased by the same percentage. This indicates a slowdown in the company's growth.

Furthermore, the company's interest costs have increased, indicating a rise in borrowings. The Operating Profit (PBDIT) for the quarter is also at its lowest in the last five quarters, and the Operating Profit Margin has decreased to -2.78%. This shows a decline in the company's efficiency.

In terms of liquidity, Sunil Healthcare's cash and cash equivalents have also decreased, while the Debtors Turnover Ratio has slowed down. The company's non-operating income has increased, but this may not be sustainable in the long run.

Overall, Sunil Healthcare's financial performance for the quarter ending December 2023 has been negative, with various factors contributing to this decline. Investors should take note of these financials before making any investment decisions.